BullFrog AI Announces New Chief Technology Officer

By December 12, 2018News, Press Releases

BullFrog AI appoints seasoned executive to lead technology and development vision

GAITHERSBURG, MARYLAND – BullFrog AI, Inc, a precision pharmaceutical company built around a powerful artificial intelligence (AI) platform, proudly announces the addition of executive Everett Lee as its Chief Technology Officer.  Mr. Lee brings nearly 3 decades of technical expertise and continuous advancement in technology management, strategic business planning and IT organizational leadership at major pharmaceutical/biotech and drug development companies such as AstraZeneca, Roche/Genentech, Eli Lilly & Co., Pfizer and Covance.

Most recently, Mr. Lee was the Global Head of IT at MedImmune, AstraZeneca’s biologics research and development arm, deploying technology that enabled scientists to advance drug candidate molecules through the pipeline for regulatory approval.  Prior to Medimmune, Mr. Lee was Head of IT for Development Sciences at Roche/Genentech in South San Francisco, California.  During those years, he led IT operations, development, and strategic evolution of all scientific applications while managing a broad cross-functional team and multi-million dollar budget to meet the informatics needs of thousands of research and development scientists.

Mr. Lee’s commitment to the industry is showcased with over 20 years of IT leadership experience in leveraging technology innovations to spur business growth and profitability in scientific and government-regulated environments.  He continues to be inspired by the mission to help patients fulfill their medical needs.  Mr. Lee earned his B.A. in Chemistry from the University of Chicago, and his M.S. in Communication Systems Strategy and Management from Northwestern University.

Mr. Lee currently lives in Maryland with his wife, 3 kids and giant furry poodle.  As a former triathlete and competitive swimmer, he enjoys living a healthy lifestyle and going on long hikes with his wife and family.  He also has a passion for digital photography and home automation technology.

“I am thrilled to have Everett as our CTO. He brings tremendous intelligence, experience, and leadership that will empower BullFrog to execute on its ambition to be the world’s premier precision pharma company,” said BullFrog AI’s CEO, Vin Singh.  “We are pushing forward to continue raising capital, build a world class leadership and technical team, and leverage our core technology that enables pharmaceutical and biotechnology companies to deliver medicines to their patients.”

Earlier this year, BullFrog announced a joint collaboration with the Lieber Institute for Brain Development to apply BullFrog AI’s proprietary artificial intelligence platform and analyze large multi-factorial clinical data sets from patients who received a leading antipsychotic medication.  BullFrog AI’s proven AI analytics engine (bfLEAPTM) helps clinicians predict which patients respond best to which medications, effectively improving clinical outcomes and eliminating the problem of trial-and-error prescriptions.

“BullFrog AI’s bold precision pharma vision and impressive technology platform are among many reasons why I joined Vin’s team,” said Mr. Lee.  “I see this as a tremendous opportunity to not only drive the AI discipline forward, but to really make a dent in the healthcare universe.  As we continue to innovate our AI platform, expand our technology offerings, partner with key pharma and biotech industry players, and grow our investor base, we will have a hand in helping to fulfill the unmet medical needs of patients all over the world.  I am deeply honored and truly delighted to be a part of this business.”

For more information on BullFrog AI, visit www.bullfrogai.com

About BullFrog AI

BullFrog AI is an innovator in artificial intelligence.  Its proprietary bfLEAPTM analytics engine is the only tool of its kind, designed to analyze massive, complex, multi-factorial clinical data sets.  BullFrog AI’s technology is poised to revolutionize drug development, enabling researchers and clinicians to match therapies to patients, streamlining clinical trials, reducing development costs and accelerating R&D cycle time to drug approval and commercial launch.  BullFrog AI has an exceptional team of life science industry leaders, AI technologists, scientists, physicians and advisors, all determined to make BullFrog AI become the undisputed leader in precision medicine.

For Media Inquiries, please contact:

Katie Guido

Thibodeau Media Group